{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:39:10Z","timestamp":1789760350158,"version":"4.0.1"},"reference-count":37,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2022,7,1]]},"DOI":"10.5551\/jat.63036","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T22:07:52Z","timestamp":1625782072000},"page":"1020-1030","source":"Crossref","is-referenced-by-count":4,"title":["Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes"],"prefix":"10.5551","volume":"29","author":[{"given":"Takao","family":"Hoshino","sequence":"first","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sono","family":"Toi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Amarenco P and Labreuche J: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol, 2009; 8: 453-463","DOI":"10.1016\/S1474-4422(09)70058-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, and Danesh J: Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009; 302: 1993-2000","DOI":"10.1001\/jama.2009.1619"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Sirimarco G, Deplanque D, Lavall\u00e9e PC, Labreuche J, Meseguer E, Cabrejo L, Guidoux C, Olivot JM, Abboud H, Lapergue B, Klein IF, Mazighi M, Touboul PJ, Bruckert E and Amarenco P: Atherogenic dyslipidemia in patients with transient ischemic attack. Stroke, 2011; 42: 2131-2137","DOI":"10.1161\/STROKEAHA.110.609727"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sirimarco G, Labreuche J, Bruckert E, Goldstein LB, Fox KM, Rothwell PM, and Amarenco P: Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke, 2014; 45: 1429-1436","DOI":"10.1161\/STROKEAHA.113.004229"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J and Perkovic V: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet, 2010; 375: 1875-1884","DOI":"10.1016\/S0140-6736(10)60656-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Despr\u00e9s JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nu\u00f1ez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner \u017d, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokg\u00f6zo\u011flu LS, Tomlinson B, Tybj\u00e6rg-Hansen A, Valensi P, Vrabl\u00edk M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A and Libby P: The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol, 2019; 18: 71","DOI":"10.1186\/s12933-019-0864-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Yamashita S, Masuda D and Matsuzawa Y: Pemafibrate, a New Selective PPAR\u03b1 Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Curr Atheroscler Rep, 2020; 22: 5","DOI":"10.1007\/s11883-020-0823-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 1993; 24: 35-41","DOI":"10.1161\/01.STR.24.1.35"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Prieto B, Miguel D, Costa M, Coto D and Alvarez FV: New quantitative electrochemiluminescence method (ECLIA) for interleukin-6 (IL-6) measurement. Clin Chem Lab Med, 2010; 48: 835-838","DOI":"10.1515\/CCLM.2010.153"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, and Post WS: Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr, 2008; 21: 93-111","DOI":"10.1016\/j.echo.2007.11.011"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet, 1998; 351: 1379-1387","DOI":"10.1016\/S0140-6736(97)09292-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O\u2019Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, and Dichgans M: Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol, 2013; 12: 822-838","DOI":"10.1016\/S1474-4422(13)70124-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Park JH, Kwon HM and Roh JK: Metabolic syndrome is more associated with intracranial atherosclerosis than extracranial atherosclerosis. Eur J Neurol, 2007; 14: 379-386","DOI":"10.1111\/j.1468-1331.2007.01682.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ritz K, Denswil NP, Stam OC, van Lieshout JJ and Daemen MJ: Cause and mechanisms of intracranial atherosclerosis. Circulation, 2014; 130: 1407-1414","DOI":"10.1161\/CIRCULATIONAHA.114.011147"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Hoshino T, Sissani L, Labreuche J, Ducrocq G, Lavall\u00e9e PC, Meseguer E, Guidoux C, Cabrejo L, Hobeanu C, Gongora-Rivera F, Touboul PJ, Steg PG, and Amarenco P: Prevalence of Systemic Atherosclerosis Burdens and Overlapping Stroke Etiologies and Their Associations With Long-term Vascular Prognosis in Stroke With Intracranial Atherosclerotic Disease. JAMA Neurol, 2018; 75: 203-211","DOI":"10.1001\/jamaneurol.2017.3960"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Yamashita S, Arai H, Yokote K, Araki E, Matsushita M, Nojima T, Suganami H and Ishibashi S: Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor \u03b1 Modulator (SPPARM\u03b1): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. Int J Mol Sci, 2019; 20: 5537","DOI":"10.3390\/ijms20225537"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nordestgaard BG and Varbo A: Triglycerides and cardiovascular disease. Lancet, 2014; 384: 626-635","DOI":"10.1016\/S0140-6736(14)61177-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) McPherson R: Remnant cholesterol: \u201cNon-(HDL-C + LDL-C)\u201d as a coronary artery disease risk factor. J Am Coll Cardiol, 2013; 61: 437-439","DOI":"10.1016\/j.jacc.2012.11.009"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Varbo A, Benn M, Tybj\u00e6rg-Hansen A and Nordestgaard BG: Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation, 2013; 128: 1298-1309","DOI":"10.1161\/CIRCULATIONAHA.113.003008"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Goldberg IJ, Eckel RH and McPherson R: Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol, 2011; 31: 1716-1725","DOI":"10.1161\/ATVBAHA.111.226100"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Nakamura T, Obata JE, Takano H, Kawabata K, Sano K, Kobayashi T, Fujioka D, Saito Y, Yano T and Kugiyama K: High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. Atherosclerosis, 2009; 202: 234-240","DOI":"10.1016\/j.atherosclerosis.2008.03.018"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R and Nordestgaard BG: Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol, 2013; 61: 427-436","DOI":"10.1016\/j.jacc.2012.08.1026"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, and Ballantyne CM: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22","DOI":"10.1056\/NEJMoa1812792"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundstr\u00f6m T, Agrawal R, Menon V, Wolski K and Nissen SE: Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA, 2020; 324: 2268-2280","DOI":"10.1001\/jama.2020.22258"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P and Ridker PM: Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J, 2018; 206: 80-93","DOI":"10.1016\/j.ahj.2018.09.011"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Ait-Oufella H, Taleb S, Mallat Z and Tedgui A: Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol, 2011; 31: 969-979","DOI":"10.1161\/ATVBAHA.110.207415"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ridker PM: Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Circ Res, 2019; 124: 437-450","DOI":"10.1161\/CIRCRESAHA.118.313129"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G and Staels B: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem, 1999; 274: 32048-32054","DOI":"10.1074\/jbc.274.45.32048"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Hennuyer N, Duplan I, Paquet C, Vanhoutte J, Woitrain E, Touche V, Colin S, Vallez E, Lestavel S, Lefebvre P and Staels B: The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis, 2016; 249: 200-208","DOI":"10.1016\/j.atherosclerosis.2016.03.003"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ogawa K, Yagi T, Guo T, Takeda K, Ohguchi H, Koyama H, Aotani D, Imaeda K, Kataoka H and Tanaka T: Pemafibrate, a selective PPAR\u03b1 modulator, and fenofibrate suppress microglial activation through distinct PPAR\u03b1 and SIRT1-dependent pathways. Biochem Biophys Res Commun, 2020; 524: 385-391","DOI":"10.1016\/j.bbrc.2020.01.118"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Konishi H, Miyauchi K, Onishi A, Suzuki S, Fuchimoto D, Shitara J, Endo H, Wada H, Doi S, Naito R, Ogita M, Dohi T, Kasai T and Daida H: Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor \u03b1 modular (SPPARM\u03b1), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury. PLoS One, 2020; 15: e0241195","DOI":"10.1371\/journal.pone.0241195"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Shinozaki S, Tahara T, Lefor AK and Ogura M: Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol, 2020; 6: 270-274","DOI":"10.5114\/ceh.2020.99528"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Seko Y, Yamaguchi K, Umemura A, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Moriguchi M, Okanoue T and Itoh Y: Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study. Hepatol Res, 2020; 50: 1328-1336","DOI":"10.1111\/hepr.13571"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Musso G, Gambino R, Cassader M and Pagano G: Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med, 2011; 43: 617-649","DOI":"10.3109\/07853890.2010.518623"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kawano Y and Cohen DE: Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol, 2013; 48: 434-441","DOI":"10.1007\/s00535-013-0758-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, and Saibara T: Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol, 2012; 47: 586-595","DOI":"10.1007\/s00535-012-0533-z"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kobayashi N, Kirikoshi H, Kubota K, Saito S and Nakajima A: Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology, 2009; 50: 772-780","DOI":"10.1002\/hep.23094"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/29\/7\/29_63036\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T05:14:36Z","timestamp":1656738876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/29\/7\/29_63036\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63036","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"63036"}}